Navigation Links
Polycythemia in Medical News

New drug for children with high-risk leukemia

... of the JAK2 in Down syndrome and leukemia causes polycythemia Vera, a disease common in adults that leads to ... completely different disorders, one that causes polycythemia in adults and the other that causes leukemia in ... JAK2," he says. "And because of the existence of polycythemia in adults, there are already drugs to ...

OHSU Cancer Institute researcher discovers what fuels certain cancer mutation

... to grow and cause a red blood cell cancer called polycythemia vera, said principal investigator Thomas Bumm, ... in Atlanta on Monday, Dec. 10, at 3:30 p.m. polycythemia vera is a disease in which there are too many red ... At this point, there is no specific treatment for polycythemia vera cancer patients. Maybe we opened a new door ...

JCI table of contents: Nov. 8, 2007

... insight into the mechanisms underlying Chuvash polycythemia and should provide a useful tool to assess the ... of red blood cells and that this causes the polycythemia in VhlR/R mice. TITLE: von HippelLindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2-alpha signaling ...

Cytopia Lodges IND for JAK2 Inhibitor CYT387

... in a variety of haematological conditions known as the myeloproliferative disorders (MPDs). This suite of conditions includes myelofibrosis, polycythemia vera and essential thrombocythemia. Cytopia has demonstrated that CYT387 inhibits the overactive JAK2 enzyme in an invivo preclinical model and in ...

Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO

... characterized by an overproduction of blood cells in the bone marrow. The MPD conditions where JAK2 mutations are most commonly found are: polycythemia vera (PV), essential thrombocytopenia (ET), and primary myelofibrosis (MF). The JAK2 signaling pathway is also known to play a critical role in the ...

Experimental Drug Fights Bone Marrow Cancers

... Bumm said in a university news release. There are no U.S. Food and Drug Administration-approved targeted treatments for the "big three" MPDs -- polycythemia vera, essential thrombocythemia and primary myelofibrosis. "Based on the efficacy we demonstrated in the mouse model, there is a good chance that ...

Stem cell research leads to potential new therapy for rare blood disorder

... author on a paper published in PNAS, outlining the discovery that a mutation in the JAK2 signaling pathway in patients with a type of MPD called polycythemia vera (PV) allows cells to bypass the process which would normally regulate the production of red blood cells. As a result of this defect, the bone ...

Top Scientists to Receive Prestigious Awards From the American Society of Hematology

... in the bone marrow. He was the first to find that a single mutation of the JAK2 gene commonly occurred in patients with three distinct disorders: polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia, a discovery which has profound implications for potential therapies. Dr. Vainchenker ...

Abnormality in the Red Blood Count Cell Poses High Risks

... hematocrit test results to improve patient outcomes." Wu and his colleagues set out to evaluate the prevalence of pre-operative anemia and polycythemia and their effects on 30-day post-operative outcomes for veterans. Wu and his team mined data from the Veterans Affairs National Surgical Quality ...
Polycythemia in Medical Technology

TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH

... of JAK2 Driven Erythroid Differentiation of polycythemia Vera -- Animesh Pardanani & Ayalew Tefferi -- ... of a Murine Model of JAK2V617F-Induced polycythemia Vera, Session Type -- Betty Tam -- TG101348: A ... of certain myeloproliferative diseases, including polycythemia vera (PV), essential thrombocytopenia (ET) and ...

Cytopia Scientific Presentations on JAK2 Inhibitor Program

... of JAK2 related patents. The main focus of the JAK2 program is developing orally available JAK2 inhibitors to treat MPDs including myelofibrosis, polycythemia vera (PV) and essential thrombocythemia (ET). CYT387 is a specific JAK2 inhibitor with excellent potential for safe and efficacious chronic human ...

Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders

... of activity in an in-vivo model of myeloproliferative disease. Myeloproliferative disorders are a group of diseases including myelofibrosis, polycythemia vera (PV) and essential thrombocythemia (ET) that affect over 150,000 patients in the USA and more than twice that worldwide. Over 95% of PV cases ...

TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients

... ) The V617F mutation of JAK2 is implicated in the pathogenesis of certain myeloproliferative diseases, including polycythemia vera (PV), essential thrombocytopenia (ET) and primary myelofibrosis (PMF). In preclinical models of myeloproliferative diseases, TG101348, ...

Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2

... drive blood cell expansion, including erythropoietin and thrombopoietin. Mutational activation of JAK2 is observed in the majority of patients with polycythemia vera, essential thrombocythemia and myelofibrosis, and is thought to drive the inappropriate expansion of blood cells observed in these conditions. ...

S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies

... in which the bone marrow develops and functions abnormally. MPD is characterised by an excess of blood cells and the three main disorders include polycythemia vera (excess red blood cell mass), essential thrombocythemia (excess blood platelets) and myelofibrosis. S*BIO is a privately-held biotech company ...
Polycythemia in Medical Definition

Hematopathology

... ( Multiple myeloma , Extramedullary plasmacytoma ) Myeloid : Myeloid leukemia ( AML , CML ) • MPD Ph- ( Essential thrombocytosis , polycythemia vera , Myelofibrosis ) • MDS • Neutropenia Red blood cells / anemia / hemoglobinopathy Nutritional anemia: ( Iron deficiency anemia ...

Pathology

... ( Multiple myeloma , Extramedullary plasmacytoma ) Myeloid : Myeloid leukemia ( AML , CML ) • MPD Ph- ( Essential thrombocytosis , polycythemia vera , Myelofibrosis ) • MDS • Neutropenia Red blood cells / anemia / hemoglobinopathy Nutritional anemia: ( Iron deficiency anemia ...
Polycythemia in Medical Dictionary

Osler

... ? Diane/ Canada ... : Cryptogenic polycythemia , Erythremia, Erythrocytosis Megalosplenica, Myeloproliferative Disorder, Osler 's Disease , polycythemia Rubra Vera, polycythemia with Chronic Cyanosis - Myelopathic ...

Polycystic Kidney

... Ovaries ( Stein -Leventhal Syndrome ) polycythemia Rubra Vera ( polycythemia Vera ) polycythemia Vera ... Polycystic kidney disease - a ...

Polycythemia

... polycythemia Related Category: Pathology ... cells, or erythrocyte s, in the blood . polycythemia vera Patients with polycythemia vera also have an increased tendency to form ...

Polycythemia vera

... polycythemia vera Patients with polycythemia vera also have an increased tendency to form ... because their platelet s are abnormal. polycythemia vera causes the red blood cells to multi ply. ...

Myeloproliferative Disorders

... with thrombocythemia, secondary to myeloproliferative disorders such as polycythemia vera (PV) and chronic myelogenous leukemia ( CML ), ... Any of a ... Myeloproliferative disorders such as primary thrombocytopenia , polycythemia vera , chronic myelogenous leukemia , ... ...

ABO incompatibility

... maternal blood mingle before birth ) Rh incompatibility ( Anti -Rh antibodies) galactosemia (see galactosemia screen) cephalo hematoma polycythemia ... Disease - ABO incompatibility Jaundice infant Antibodies Definition: ABO incompatability describes an immune reaction that ...

Biliary atresia

... factors which can potentiate jaundice in the newborn include: sepsis , biliary atresia , Rh incompatibility, galactosemia , cephalo hematoma , polycythemia , G-6-P-D deficiency , and congenital rubella , syphilis , toxoplasmosis , ... ...

Blood disorders

... Ears and Hearing Disorders Eating Disorders Endocrine Disorders ... Less common causes of TIA include blood disorders (including polycythemia , sickle cell anemia , and hyperviscosity syndrome s where the blood is very thick), spasm of the small arteries in the brain, ... Skin ...

Blood typing

... blood typing - to check the blood group (A, B, O) and the Rh factor (positive or negative) testing for anemia (too few red blood cells) or polycythemia (too many red blood cells) testing for infection in the blood , urine , or spinal fluid ... RhA blood typing group, like the ABO system. ...

CBC

... s. Blood tests - A complete blood count ( CBC ) can show if there are too few red blood cells ( anemia ) or too many red blood cells ( polycythemia ), either of which can be seen in people with kidney cancer . Chest x-ray reveals pulmonary infiltrates and complete blood count ( CBC ) ...

More>>

Polycythemia in Biological News

Mutation in blood stem cells provides clues to cancer development

... A mutation in blood stem cells occurs in patients with a blood disorder called polycythemia vera (PV), scientists at the Moores Cancer Center at the University of California, San Diego (UCSD) and the Institute for Stem Cell Biology and ...
Polycythemia in Biological Technology

Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference

... of JAK2 related patents. The main focus of the JAK2 program is developing orally available JAK2 inhibitors to treat MPDs including myelofibrosis, polycythemia vera and essential thrombocythemia. CYT387 is a specific JAK2 inhibitor with excellent potential for safe and efficacious chronic human dosing. ...
Other Contents
(Date:8/21/2014)... August 21, 2014 The new ... from Lockton Companies and builds on Accountable Health ... cellular glucometer, combined with Accountable Health’s robust member ... analytic capabilities and adds a custom incentive platform ... eye exams, provider visits, HbA1c testing and more. ...
(Date:8/21/2014)... 21, 2014 Relias Learning, the leader ... and human services markets, announced the latest release of ... the Tin Can API. , “Supporting the Tin ... the most advanced mobile learning capabilities and the ability ... tools and techniques,” says Jim Triandiflou, CEO of Relias ...
(Date:8/21/2014)... to be elicited by T-type calcium channels in ... regulate influxes of calcium. These channels enable thalamic ... the neurons to enter a hyper-excited state. , ... firing and absence seizures, the researchers conducted an ... gene targeting techniques to delete the T-type calcium ...
(Date:8/21/2014)... August 21, 2014 ... Peripheral Vascular Devices Market by Angioplasty ... Catheter (IVUS, OCT), IVC Filter (Retrievable), ... 2018" analyzes and studies the major ... the U.S. and Canada. , Browse ...
(Date:8/21/2014)... mynt welcomes industry leaders Rob and ... its growing company. Since its pre-launch in April, mynt ... and continues to gain momentum leading up to its ... Tiffanie came into network marketing by chance. Tiffanie worked ... network marketing companies. Tiffanie needed help at one particular ...
Breaking Medicine News(10 mins):Health News:Accountable Health Expands Diabetes Management Solutions to Address Gaps in Provider Care 2Health News:Accountable Health Expands Diabetes Management Solutions to Address Gaps in Provider Care 3Health News:Relias Learning Announces Support for Tin Can API 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5Health News:Industry Leaders Rob and Tiffanie Moffitt Join mynt 2
(Date:8/20/2014)... scientists have discovered that acral melanomas the rare type ... are genetically distinct from other more common types of ... in the journal Pigment Cell & Melanoma Research . ... hands, soles of the feet, nail-beds and other hairless parts ... it,s not caused by UV damage from the sun. , ...
(Date:8/20/2014)... plastic bags could one day be made out of ... are now reporting. The novel process they developed and ... its agricultural and plastic waste problems, appear in the ... S. Bayer and colleagues at the Italian Institute of ... In 2012, its production reached 288 million tons worldwide, ...
(Date:8/20/2014)... 1 (PS1) absorbs light and its energy is ... to biomass. Photovoltaic devices, mostly build from silicon ... electricity. One approach for the development of cheaper ... with the isolated membrane protein complexes of photosynthesis. ... stable PS1 from thermophilic cyanobacteria that live in ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2A semi-artificial leaf faster than 'natural' photosynthesis 2
Other TagsOther Tags